News

Findings from a phase 3 trial published in JAMA Oncology suggest allo-HCT may not provide an OS benefit for patients with intermediate-risk acute myeloid leukemia during first complete remission.

Identifying alterations to tailor treatment is important for patients with pediatric low-grade glioma as it accounts for one-third of all pediatric central nervous system tumors.

Despite a favorable vote by the Oncologic Drugs Advisory Committee, the FDA has opted not to approve remestemcel-L for the treatment of pediatric steroid-refractory acute graft-vs-host disease.

A retrospective study of the CATCH-IT database provided data on patients with HIV who received immunotherapy for multiple cancer types, demonstrating safety and efficacy in most cases.

ABM-1310 is a novel small molecule BRAF inhibitor that has shown promising anti-cancer activity and a good safety profile across a variety of advanced BRAF V600-mutant solid tumors.

Michael Wang, MD, discusses where future research efforts for pirtobrutinib will be focused for patients with relapsed/refractory mantle cell lymphoma.

Gilteritinib can be a promising bridge to allogeneic hematopoietic stem cell transplantation, according to data at the European Society for Blood and Marrow Transplantation 49th Annual Meeting.

Sagun Shrestha, MD, discusses new trials that are exploring anti PD-1 therapy in the first-line setting for patients with small cell lung cancer.

Trifluridine/tipiracil plus bevacizumab improved rates of progression-free and overall survival vs trifluridine/tipiracil alone in the SUNLIGHT study. Now, the combination is FDA-approved for patients with metastatic colorectal cancer.

The phase 1 study is evaluating the combination of a CD19-targeting chimeric antigen receptor and an orthogonal IL-2 in patients with CD19-positive hematologic malignancies.

Topline results reported from the UPLIFT trial showed it did not meet its primary end point of objective response rate in the NaPi2b-positive population with ovarian cancer.

A promising disease control rate and overall response rate was seen with elraglusib when given with chemotherapy for patients with pancreatic cancer, according to phase 2 study findings.

The REACH3 study showed ruxolitinib to elicit a high efficacy rate and have a manageable safety profile in patients with chronic graft-versus-host disease.

Matthew Powell, MD, discusses findings from the phase 3 RUBY/ENGOT-EN6/GOG3031/NSGO trial of dostarlimab in combination with chemotherapy for patients with mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer.

In an interview with Targeted Oncology, Robert L. Coleman, MD, FACOG, FACS, discussed real-world findings from a trial evaluating second-line maintenance niraparib in patients with recurrent ovarian cancer.

In an interview with Targeted Oncology, Antonio Ucar, MD, discussed the evolving role of sunitinib for the second-line treatment of gastrointestinal stromal tumors, and the Peak study.

IVS-3001, a chimeric antigen receptor therapy developed to target and kill HLA-G-bearing cells, is currently in late-stage preclinical development for the treatment of solid tumors.

Results from the CARTITUDE-2 trial of cilta-cel for multiple myeloma support the use of chimeric antigen receptor T-cell therapy earlier in therapy than what is currently approved.

KEYNOTE-756 is the first positive phase 3 study to generate a statistically significant improvement in pathological complete response rate with an immunotherapy regimen in the neoadjuvant setting for ER-positive/HER2-negative breast cancer.

FDA approval has been granted to dostarlimab in combination with chemotherapy for the treatment of patients with mismatch repair deficient and microsatellite instability-high primary advanced or recurrent endometrial cancer.

Although no safety or efficacy issues were reported in the biologics license application for denileukin diftitox for cutaneous T-cell lymphoma, a complete response letter has been issued.

The phase 3 QuANTUM-First trial showed that quizartinib plus chemotherapy with or without allogeneic hematopoietic stem cell transplant improved overall survival in patients with acute myeloid leukemia with a FLT3-ITD mutation.

ctDNA sequencing can efficiently detect KIT/PDGFRA mutations and predict outcomes in patients with tyrosine kinase inhibitor-resistant gastrointestinal stromal tumor treated with avapritinib.

Ghassan K. Abou-Alfa, MD, discusses the phase 3 RATIONALE-301 trial of frontline tislelizumab vs sorafenib in patients with hepatocellular carcinoma.

Phase 1 results with the KRAS G12C inhibitor garsorasib did not show an immediate advantage with the latest KRAS G12C inhibitor but show that investigations into these inhibitors continue to grow.

Increased understanding of the tumor microenvironment, the importance of molecular abnormalities, and the signaling pathways of cytokines has finally yielded more effective, tumor-specific therapies.

Topline data from the phase 3 ATLAS and ENVISION trials of UGN-102 showed a robust and consistent therapeutic profile when used for patients with low-grade, intermediate-risk non-muscle invasive bladder cancer.

Positive topline results from the AGAVE-201 trial have led the companies to submit a biologics license application to the FDA by the end of 2023.

Data from 2 studies, LIGHTHOUSE and SPOTLIGHT, have shown the benefit of flotufolastat F 18 injection as a radiohybrid PSMA-targeted pet imaging agent in prostate cancer. The agent has now been added to the NCCN guidelines.

Primary results from the phase 1 COVALENT 101 study demonstrate the potential of BMF-219 to induce responses in patients with various relapsed or refractory leukemias/lymphomas, including acute myeloid leukemia.